Instruments

Name Stock exchange Average volume Price Type
KEN HOLDINGS KEN

BURSA MALAYSIA

20,793 0.6 MYR Stock Ken Holdings Stock
KEN FINANCIAL SERVICES LIMITED KENFIN

Bombay S.E.

5,906 25.08 INR Stock Ken Financial Services Limited Stock
KEN HOLDING CO., LTD. 300126

Shenzhen S.E.

3,819,741 4.49 CNY Stock Ken Holding Co., Ltd. Stock
RSE ARCHIVE LLC - MEMBERSHIP INTERESTS SERIES - 1989 BOWMAN KEN GRIFFEY JR FUND RKGJS

OTC Markets

- 7.75 USD Stock RSE Archive LLC - Membership Interests Series - 1989 Bowman Ken Griffey Jr Fund Stock

News (128)

Transcript : Daiichi Sankyo Company, Limited - Special Call
Daiichi Sankyo : ASCO highlight briefing session materia PU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy BU
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy BU
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial BU
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial BU
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO BU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow BU
AstraZeneca makes progress with Truqap and Enhertu cancer treatments AN
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial BU
Transcript : Daiichi Sankyo Company, Limited, 2024 Earnings Call, Apr 25, 2024
AstraZeneca, Daiichi make US progress with licence approvals AN
AstraZeneca : Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer - Form 6-K PU
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer BU
AstraZeneca and Daiichi make US progress with latest licence approvals AN
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer BU
AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment AN
AstraZeneca : Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer PU
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer BU
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer BU
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer BU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors BU
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors BU
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer BU
Daiichi Sankyo : Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer(260.3KB PU
Transcript : Daiichi Sankyo Company, Limited - Special Call
Transcript : Daiichi Sankyo Company, Limited - Special Call
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial BU
AstraZeneca : Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial PU
Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial BU
Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMO BU
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial BU
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial BU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial BU
AstraZeneca : Enhertu demonstrated strong and durable tumour responses in previously treated HER2-mutant advanced lung cancer in DESTINY-Lung02 Phase II trial PU
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial BU
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial BU
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers BU
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients with Lung Cancer with Data Across DXd ADC Portfolio at WCLC BU
Transcript : Daiichi Sankyo Company, Limited, Q1 2024 Earnings Call, Jul 31, 2023
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial BU
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial BU
Transcript : Daiichi Sankyo Company, Limited - Analyst/Investor Day
Daiichi Sankyo : Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA(248.5KB PU
Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA BU
1234NextSee all

Companies (6)

KEN HOLDINGS 23 M $
Logo Ken Holdings

KEN Holdings Berhad is a Malaysia-based company, which is engaged in investment holding and the provision of management services. The Company's segments include Construction, Property development and Property investment. The Construction segment offers sp ...

JENSCARE SCIENTIFIC CO., LTD. 202 M $
Logo Jenscare Scientific Co., Ltd.

Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The Company develops interventional products for the treatment of structural heart disease. The Company's core product ...

KEN HOLDING CO., LTD. 173 M $
Logo Ken Holding Co., Ltd.

Ken Holding Co Ltd is a China-based company mainly engaged in the research and development (R&D), production and sales of professional electric tools. The Company's products include brand products and conventional products. The brand products include new ...

ENDURO METALS CORPORATION 6 M $
Logo Enduro Metals Corporation

Enduro Metals Corporation is a Canada-based exploration company focused on its flagship Newmont Lake Project. The Company is engaged in the identification, acquisition, and exploration of prospective mineral properties in Canada. The Newmont Lake project ...

COMPTOIR GROUP PLC 10 M $
Logo Comptoir Group PLC

Comptoir Group Plc is a United Kingdom-based owner and operator of restaurants, which is engaged in offering Lebanese in the United Kingdom casual dining sector. The Company operates through the restaurants with Lebanese and Middle Eastern offering segmen ...

MONRO, INC. 739 M $
Logo Monro, Inc.

Monro, Inc. is an operator of retail tire and automotive repair stores in the United States. The Company offers replacement tires and tire related services, automotive undercar repair services, and a range of routine maintenance services, primarily on pas ...


Insiders


Picture Ken Takeshita
Ken Takeshita

Dr. Ken Takeshita, MD, is a Global Director-Research & Development at Daiichi Sankyo Co., Ltd. Dr. Takeshita was previously employed as a Senior VP & Global Head-Clinical Development by Kite Pharma, Inc.


Picture Ken Takeshita
Ken Takeshita

Ken Takeshita is currently the Chief Executive Officer at Ambit Biosciences Corp.


Picture Noriaki Takeshita
Noriaki Takeshita

Noriaki Takeshita is on the board of Rabigh Refining & Petrochemical Co. and Representative Director at Sumitomo Chemical Co., Ltd. In the past he held the position of Manager-Planning & Coordination Office at Petrochemical Corporation of Singapore Pte Ltd. Mr. Takeshita received a graduate degree from the University of Tokyo.


Picture Ken Kutaragi
Ken Kutaragi

Presently, Ken Kutaragi holds the position of President, CEO & Representative Director at Cyber AI Entertainment, Inc. and Chief Executive Officer for Ascent Robotics, Inc. Mr. Kutaragi is also on the board of Rakuten, Inc., SmartNews, Inc. and GA technologies Co., Ltd. In the past he occupied the position of Deputy President, COO & Director at Sony Corp. and Chairman & Group Chief Executive Officer at Sony Computer Entertainment, Inc. (a subsidiary of Sony Corp.).


Picture Ken Miyauchi
Ken Miyauchi

Mr. Ken Miyauchi is a Chairman at SoftBank Commerce & Services Corp. and a Chairman at SoftBank Corp. He is on the Board of Directors at SoftBank Group Corp. Mr. Miyauchi was previously employed as an Executive Officer by Softbank Group Japan Godokaisha, a President & Representative Director by WILLCOM, Inc., a COO, Representative Director & Vice President by Softbank Telecom Corp., an Outside Director by Carview Corp., and a COO, Representative Director & Vice President by SOFTBANK BB Corp. He also served on the board at Brightstar Global Group, Inc., eAccess Ltd., Z Holdings Corp. and Brightstar International Corp.


Picture Ken Hashimoto
Ken Hashimoto

Ken Hashimoto is an Independent Outside Director at TAKARA STANDARD CO., LTD.
since 2017.
He previously worked as Director, Head-Finance & Accounting at Kao Corp.
and as an Independent Non-Executive Outside Director at Itochu-Shokuhin Co., Ltd.


Picture Ken Norgrove
Ken Norgrove

Ken Norgrove is currently the Chief Executive Officer & Director at RSA Insurance Group Ltd.
and the Chief Executive Officer at Scandi Co. 3 A, Trygg Hansa Försakring AB, and Royal & Sun Alliance Insurance Ltd.
He previously held positions as the Chief Executive Officer at RSA Insurance Group Ltd., Zurich Insurance Co., Codan Forsikring A, and RSA Insurance Ireland DAC.
He also served as a Director at Insurance Ireland, Vice President at Travelers Insurance Co. Ltd., and President at the Insurance Institute of Ireland.


Picture Ken Takayama
Ken Takayama

Ken Takayama currently works at TechMatrix Corp., as Independent Outside Director from 2015 and Mercari, Inc., as Independent Outside Director from 2018.
Mr. Takayama also formerly worked at Rakuten Group, Inc., as CFO, Director & Investor Relations Contact in 2012, MEDIA DO Co., Ltd., as Independent Outside Director, Metaps, Inc., as Independent Outside Director, Star Festival, Inc., as Outside Director, and Mizuho Bank Ltd., as Principal.
Mr. Takayama received his Masters Business Admin degree in 1994 from The University of Texas at Austin and undergraduate degree from Hitosubashi University.


Picture Ken Thomas
Ken Thomas

Ken Thomas is currently the Chief Information Officer at The Hain Celestial Group, Inc. He previously worked as the Chief Information Officer at McCormick & Co., Inc. He holds a Master's degree in Business Administration from Loyola University Maryland, Inc.


Picture Ken Uehara
Ken Uehara

Presently, Ken Uehara is Director, Head-Audit & IT Planning at Taisho Pharmaceutical Holdings Co., Ltd. and Chairman of Biofermin Pharmaceutical Co., Ltd. and Representative Director & Vice President at Taisho Pharmaceutical Co., Ltd. (both are subsidiaries of Taisho Pharmaceutical Holdings Co., Ltd.).


Picture Ken Yamaguchi
Ken Yamaguchi

Ken Yamaguchi holds the position of Chief Medical Officer & Executive Vice President at Centene Corp. He previously was Treasurer & Director at American Academy of Orthopaedic Surgeons. Dr. Yamaguchi received an MBA from the University of Washington.


Ken Xie
Ken Xie

Ken Xie is the founder of Fortinet, Inc. (founded in 2000) and NetScreen Technologies, Inc. (founded in 1993).
He is currently the Chairman & Chief Executive Officer of Fortinet, Inc. Mr. Xie is also the founder of Stanford Infosystems International, Inc. Mr. Xie's current jobs include being a Director at Hua Yuan Science & Technology Association, a Director at Cyber Threat Alliance, a Member of the National Academy of Engineering, a Member of the Committee of 100, a Member of the Silicon Valley Leadership Group, a Member of The World Economic Forum USA, Inc. - Center of Cyber Security, and an Advisor at ForgePoint Capital Management LLC.
Mr. Xie's former jobs include being the Chief Executive Officer of Systems Integration Solutions, Inc., an Independent Director at TeleNav, Inc., a Director at ZingBox, Inc., a Principal at Emdeon Corp., and a Member - Center for Cybersecurity at Forum Mondial de L'Economie.
Mr. Xie's education includes a graduate degree from Stanford University and undergraduate and graduate degrees from Tsinghua University.


Picture Ken Harris
Ken Harris

Ken Harris occupies the position of Chief Information Officer at Shaklee Corp. In his past career Mr. Harris occupied the position of Chief Operating & Information Officer at PepsiCo, Inc., Chief Information Officer & Senior Vice President for NIKE, Inc. and Chief Information Officer & Senior Vice President of Gap, Inc. He received an undergraduate degree from Colorado State University.


Picture Ken Patel
Ken Patel

Presently, Ken K. Patel occupies the position of Chief Ethics & Compliance Officer at Procter & Gamble Co. Mr. Patel is also on the board of The Mercantile Library of Cincinnati, Cincinnati Chamber of Commerce and Uc College of Law and Chairman of Council of Better Business Bureaus, Inc. He received a graduate degree from the University of Cincinnati (Ohio) and an undergraduate degree from Purdue University.


Picture Ken Anderson
Ken Anderson

Ken Anderson is currently the Chief Finance Officer & Director at RSA Insurance Group Ltd.
He previously worked as a Safety Director at Genesee-Bay Constructors, Inc.


Picture Ken Tourangeau
Ken Tourangeau

Ken Tourangeau is Executive Vice President of TFI International, Inc. He received an undergraduate degree from HEC Montréal.


Picture Ken Stillwell
Ken Stillwell

Mr. Ken Stillwell is a COO, CFO, Chief Administrative Officer & SVP at Pegasystems, Inc. Mr. Stillwell was previously employed as a Chief Financial Officer & Senior Vice President by Dynatrace LLC, a Divisional Chief Financial Officer by PTC, Inc., a Chief Financial Officer & Vice President-Finance by Inmedius, Inc., a Chief Operating Officer by Milestone Group LLC, a Principal by Pricewaterhousecoopers LLC, and a Chief Financial Officer & Executive Vice President by Sovos Compliance LLC. He received his undergraduate degree from the University of Pittsburgh and a graduate degree from the University of South Carolina.


Picture Ken Uchida
Ken Uchida

Ken Uchida occupies the position of Director, Managing Executive Officer & GM-Finance at Kajima Corp. In the past Mr. Uchida occupied the position of President & Director at Kajima Europe Ltd.


Picture Ken Sato
Ken Sato

Founder of ROHM Co., Ltd., Ken Sato is on the board of ROHM Co., Ltd. (former President & Representative Director) and Chairman at Rohm Music Foundation.


Picture Ken Corless
Ken Corless

Ken Corless is Executive VP-Technology, Offerings & Partners at DXC Technology Co. He received an undergraduate degree from Massachusetts Institute of Technology.


Ken Murphy
Ken Murphy

Ken Murphy is on the board of Boots International Ltd. and Soap & Glory Ltd. In his past career he held the position of Executive Vice President at Walgreens Boots Alliance, Inc.


Picture Ken Fujiwara
Ken Fujiwara

Presently, Ken Fujiwara is Director & Chief Compliance Officer at Mitsubishi Chemical Holdings Corp. and Chief Executive Officer for Mitsubishi Chemical Holdings Europe GmbH (a subsidiary of Mitsubishi Chemical Holdings Corp.). Mr. Fujiwara is also on the board of Mitsubishi Tanabe Pharma Corp. Ken Fujiwara previously held the position of Chief Executive Officer of Mitsubishi Chemical Holdings America, Inc.


Picture Ken Grady
Ken Grady

Ken Grady is Chief Information Officer & Senior VP at IDEXX Laboratories, Inc. In his past career Mr. Grady occupied the position of Chief Information Officer at New England Biolabs, Inc. and Global Head-Business Analytics at Novartis Vaccines & Diagnostics, Inc. He received an undergraduate degree from Georgia Institute of Technology.


Picture Ken Widner
Ken Widner

Ken Widner currently works at Casey's General Stores, Inc., as Vice President-IT Engineering.



Ken Fisher
Ken Fisher

Presently, Ken Fisher holds the position of Chief Technology Officer & Vice President at Kimco Realty Corp. In his past career he held the position of Manager for Deloitte & Touche LLP. Mr. Fisher received an undergraduate degree from The Johns Hopkins University and a graduate degree and an MBA from the University of Florida.


Picture Ken Kobayashi
Ken Kobayashi

Ken Kobayashi is on the board of Mitsubishi Heavy Industries, Ltd., Mitsubishi Motors Corp. and Nissin Foods Holdings Co., Ltd. and Chairman of Mitsubishi Corp.


Picture Ken Werner Østreng
Ken Werner Østreng

Presently, Ken Werner Østreng occupies the position of Chief Financial Officer for Kahoot! AS. He is also on the board of Confirmit Ltd. (former Chief Financial Officer). In the past Mr. Østreng occupied the position of President & Chief Executive Officer for Confirmit AS, Chief Financial Officer of E-Line Group ASA, Chief Financial Officer at Conax AS and Controller-Group Finance at Telenor ASA. Ken Werner Østreng received an undergraduate degree from Norwegian School of Information Technology.


Picture Kenji Takeshita
Kenji Takeshita

Kenji Takeshita worked as a Managing Director at Chuetsu Pulp & Paper Co., Ltd.
from 1967 to 2010.









Picture Kenji Takeshita
Kenji Takeshita

Kenji Takeshita served as Director, Vice President & GM-Administration at Stream Co., Ltd.
from 2007 to 2012.
He also worked as Chief Financial Officer & Director at I & C-Cruise Co., Ltd.




Picture Masanori Takeshita
Masanori Takeshita

Masanori Takeshita worked as a Director at S-cubism, Inc. and as a Principal at Future Corp.
He received an undergraduate degree from Osaka University in 2002.








Picture Takeshita Hironobu
Takeshita Hironobu

Takeshita Hironobu is currently a member of the supervisory board at Hanwa Trading (Shanghai) Co., Ltd.




















Picture Tomohiko Takeshita
Tomohiko Takeshita

Tomohiko Takeshita is currently a Senior Managing Director at CURRENT MOTOR Corp.
He graduated from Waseda University with an undergraduate degree in 2001.


Picture Michio Takeshita
Michio Takeshita

Michio Takeshita worked at UBE Corp.
from 1973 to 2019 and held the position of Director in 2019.



Picture Nobuyuki Takeshita
Nobuyuki Takeshita

Nobuyuki Takeshita worked as an Auditor at Bunka Shutter Co. Ltd.
from 1971 to 2012.



Picture Takafumi Takeshita
Takafumi Takeshita

Takafumi Takeshita currently works at Net One Systems Co., Ltd., as Executive President, CEO & Representative Director from 2022 and Net One Connect GK, as President & Representative Director from 2019.


Picture Shunichi Takeshita
Shunichi Takeshita

Shunichi Takeshita currently works at Zaiju Biz KK, as Chairman from 2022 and Tama Home Co., Ltd., as Director from 2022.


Picture Davi Takeshita
Davi Takeshita

Davi Takeshita worked as a Portfolio Manager at Bram Bradesco Asset Management S from 2016 to 2022, at CA Indosuez Wealth (Brasil) SA DTVM from 2005 to 2011, and at Agora Gestão de Recursos Ltda.
from 2011 to 2016.
He also worked as a Portfolio Manager at Gauss Capital Gestora de Recursos Ltda.
from 2022 to 2023.







Picture Masafumi Takeshita
Masafumi Takeshita

Masafumi Takeshita is currently working as the Managing Executive Officer & GM-Sales at Krosaki Harima Corp.


Picture Kenichi Takeshita
Kenichi Takeshita

Kenichi Takeshita worked as a Managing Director & General Manager-Business at Nichizo Tech, Inc. and as an Auditor at Hitachi Zosen Fukui Corp.






Picture Koichiro Takeshita
Koichiro Takeshita

Koichiro Takeshita served as an Independent Director at Spectral Medical, Inc. from 2015 to 2016.
He also worked as a Director in the Medical Device Division at Toray Industries, Inc. Mr. Takeshita completed his undergraduate degree at the University of Tokyo.







Picture Shunichi Takeshita
Shunichi Takeshita

Shunichi Takeshita is the founder and current Chief Executive Officer of GATARI, Inc. which is founded in 2016.




Picture Shoichi Takeshita
Shoichi Takeshita

Shoichi Takeshita currently works at Miyoshi Oil & Fat Co., Ltd., as COO & Managing Representative Director from 2023.




Picture Yoshikazu Takeshita
Yoshikazu Takeshita

Yoshikazu Takeshita is currently the President & Representative Director at Hisaka Works Ltd.
He completed his undergraduate degree from Kyoto Institute of Technology in 1981.



No results for this search